A conceptual framework from Heilongjiang University positions metainflammation — chronic low-grade inflammation arising from adipose tissue dysfunction and metabolic surplus — as the mechanistic bridge between preclinical obesity and overt cardiovascular disease. The model identifies three interdependent drivers: immune cell heterogeneity within adipose tissue, mitochondrial dysfunction with redox stress, and senescent cells secreting a pro-inflammatory SASP (senescence-associated secretory phenotype). Critically, the framework argues this inflammatory cascade requires a permissive metabolic milieu — dyslipidemia, insulin resistance, and genetic susceptibility — to precipitate clinical events. Screening biomarkers hsCRP and IL-6 are proposed to identify high-inflammatory phenotypes before end-organ damage.
This is a theory paper, not original clinical data, so its direct evidential weight is limited. However, it synthesizes a genuinely useful clinical architecture. The tiered intervention ladder — lifestyle modification, statins (leveraging pleiotropic anti-inflammatory effects), GLP-1 receptor agonists, then senolytics — maps neatly onto emerging evidence from CANTOS, DECLARE-TIMI 58, and early senolytic trials. The GLP-1 agonist inclusion is timely given mounting cardiovascular outcome data from semaglutide trials. The senolytic tier remains the most speculative, with human cardiovascular outcome data largely absent. For practitioners, the framework's main value is repositioning obesity management from a metabolic to an immunometabolic problem — reframing statin and GLP-1 prescribing as anti-inflammatory, not merely lipid or glucose interventions. Confirmatory, but usefully integrative.
